Biogen Inc. (BIIB) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 04/25/23
Alzheimer's Drugs Still Aren't Biogen's Saving Grace — But The Company Is HopefulInvestors Business Daily • 04/25/23
Alzheimer's patients retain the benefits of Leqembi even when they stop the drug, Eisai saysCNBC • 04/06/23
Ionis And Biogen: Tofersen PDUFA Looms - Positive Outcome May Kick Off Bull Run For Both StocksSeeking Alpha • 04/06/23
Additional Detailed Analyses From Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed JournalsGlobeNewsWire • 03/30/23
Eisai Presented New Analyses of ARIA and QOL on Lecanemab in Clarity AD at the AD/PD™ 2023 Annual MeetingGlobeNewsWire • 03/30/23
New Data Presented at AD/PD™ 2023 Show Biogen's BIIB080 (MAPT ASO) Substantially Reduced Tau Protein Levels in Patients with Early-stage Alzheimer's DiseaseGlobeNewsWire • 03/29/23
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALSGlobeNewsWire • 03/23/23
FDA advisors vote against effectiveness of Biogen's ALS drug for rare and aggressive form of the diseaseCNBC • 03/22/23
FDA staff says Biogen's ALS drug may have a 'clinical benefit' on a rare form of the diseaseCNBC • 03/20/23